MCID: RSP006
MIFTS: 50

Respiratory System Disease

Categories: Respiratory diseases

Aliases & Classifications for Respiratory System Disease

MalaCards integrated aliases for Respiratory System Disease:

Name: Respiratory System Disease 12 15 17
Abnormality of the Respiratory System 29 6
Respiratory Tract Diseases 71
Respiration Disorders 71

Classifications:



External Ids:

Disease Ontology 12 DOID:1579
ICD9CM 34 510-519.99 519
ICD10 32 10 J96-J99 J98
UMLS 71 C0029582 C0035204 C0035242

Summaries for Respiratory System Disease

Disease Ontology : 12 A disease of anatomical entity that located in the respiratory system which extends from the nasal sinuses to the diaphragm.

MalaCards based summary : Respiratory System Disease, also known as abnormality of the respiratory system, is related to upper respiratory tract disease and pulmonary disease, chronic obstructive, and has symptoms including dyspnea, edema and respiratory distress. An important gene associated with Respiratory System Disease is MIR199A1 (MicroRNA 199a-1), and among its related pathways/superpathways are MicroRNAs in cancer and Parkinsons Disease Pathway. The drugs Ciprofloxacin and Cefuroxime have been mentioned in the context of this disorder. Affiliated tissues include respiratory system which extends from the nasal sinuses to the diaphragm, lung and testes.

Related Diseases for Respiratory System Disease

Diseases related to Respiratory System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 272)
# Related Disease Score Top Affiliating Genes
1 upper respiratory tract disease 33.0 SERPINA3 MIR9-1 MIR486-1 MIR34C MIR31 MIR30A
2 pulmonary disease, chronic obstructive 31.1 SERPINA3 MIR199A1 MIR142 MIR126 ICOSLG H2AC18
3 pulmonary fibrosis, idiopathic 30.9 MIR34C MIR21 MIR199A1 MIR196A1 MIR142 MIR140
4 idiopathic interstitial pneumonia 30.8 MIR21 MIR199A1 MIR142 CCR6
5 nervous system disease 11.0 SERPINA3 MIR9-1 MIR486-1 MIR34C MIR31 MIR30A
6 bone inflammation disease 11.0 SERPINA3 MIR30A MIR21 MIR199A1 MIR196A1 MIR17
7 arteries, anomalies of 11.0 SERPINA3 MIR9-1 MIR486-1 MIR30A MIR21 MIR199A1
8 leukocyte disease 11.0 SERPINA3 MIR9-1 MIR486-1 MIR30A MIR21 MIR200B
9 nervous system cancer 11.0 SERPINA3 MIR9-1 MIR486-1 MIR34C MIR30A MIR21
10 glucose metabolism disease 11.0 SERPINA3 MIR9-1 MIR486-1 MIR30A MIR21 MIR199A1
11 leukemia, acute myeloid 11.0 SERPINA3 MIR9-1 MIR486-1 MIR34C MIR30A MIR21
12 eye disease 11.0 SERPINA3 MIR9-1 MIR486-1 MIR30A MIR21 MIR199A1
13 overnutrition 11.0 SERPINA3 MIR9-1 MIR486-1 MIR21 MIR199A1 MIR196A1
14 renal cell carcinoma, nonpapillary 11.0 MIR9-1 MIR486-1 MIR30A MIR21 MIR199A1 MIR196A1
15 skin disease 11.0 SERPINA3 MIR31 MIR21 MIR199A1 MIR17 MIR155
16 lung cancer 11.0 SERPINA3 MIR9-1 MIR486-1 MIR34C MIR31 MIR30A
17 immune system disease 11.0 SERPINA3 MIR9-1 MIR30A MIR21 MIR200B MIR199A1
18 central nervous system disease 11.0 SERPINA3 MIR9-1 MIR34C MIR30A MIR21 MIR199A1
19 prostate disease 11.0 SERPINA3 MIR9-1 MIR486-1 MIR34C MIR31 MIR30A
20 esophageal disease 11.0 MIR486-1 MIR30A MIR21 MIR200B MIR199A1 MIR196A1
21 lymphoma, non-hodgkin, familial 11.0 SERPINA3 MIR9-1 MIR486-1 MIR30A MIR21 MIR200B
22 ovary epithelial cancer 11.0 SERPINA3 MIR34C MIR30A MIR21 MIR199A1 MIR196A1
23 bone marrow cancer 11.0 MIR9-1 MIR30A MIR21 MIR199A1 MIR196A1 MIR17
24 malignant ovarian surface epithelial-stromal neoplasm 11.0 SERPINA3 MIR34C MIR30A MIR21 MIR199A1 MIR196A1
25 body mass index quantitative trait locus 11 11.0 SERPINA3 MIR9-1 MIR486-1 MIR21 MIR199A1 MIR196A1
26 myeloma, multiple 11.0 MIR30A MIR21 MIR199A1 MIR196A1 MIR17 MIR155
27 endocrine system disease 11.0 SERPINA3 MIR9-1 MIR486-1 MIR34C MIR31 MIR30A
28 autosomal genetic disease 11.0 SERPINA3 MIR9-1 MIR486-1 MIR21 MIR199A1 MIR196A1
29 urinary system disease 11.0 SERPINA3 MIR9-1 MIR486-1 MIR31 MIR30A MIR21
30 pancreas disease 11.0 SERPINA3 MIR9-1 MIR486-1 MIR34C MIR31 MIR30A
31 acquired metabolic disease 11.0 SERPINA3 MIR9-1 MIR486-1 MIR31 MIR30A MIR21
32 gonadal disease 11.0 SERPINA3 MIR9-1 MIR486-1 MIR34C MIR31 MIR30A
33 gastrointestinal system disease 11.0 SERPINA3 MIR9-1 MIR486-1 MIR34C MIR31 MIR30A
34 leukemia, chronic lymphocytic 11.0 MIR9-1 MIR486-1 MIR31 MIR30A MIR21 MIR199A1
35 lung cancer susceptibility 3 11.0 SERPINA3 MIR9-1 MIR486-1 MIR31 MIR30A MIR21
36 intestinal disease 11.0 SERPINA3 MIR9-1 MIR486-1 MIR34C MIR31 MIR30A
37 thoracic cancer 11.0 SERPINA3 MIR9-1 MIR486-1 MIR34C MIR31 MIR30A
38 male reproductive system disease 11.0 SERPINA3 MIR9-1 MIR486-1 MIR34C MIR31 MIR30A
39 reproductive system disease 11.0 SERPINA3 MIR9-1 MIR486-1 MIR34C MIR31 MIR30A
40 colonic disease 11.0 MIR9-1 MIR486-1 MIR31 MIR30A MIR21 MIR200B
41 male reproductive organ cancer 11.0 SERPINA3 MIR9-1 MIR486-1 MIR34C MIR31 MIR30A
42 gastrointestinal system cancer 11.0 SERPINA3 MIR9-1 MIR486-1 MIR34C MIR31 MIR30A
43 hematologic cancer 11.0 SERPINA3 MIR9-1 MIR486-1 MIR34C MIR31 MIR30A
44 connective tissue cancer 11.0 SERPINA3 MIR9-1 MIR31 MIR21 MIR199A1 MIR196A1
45 female reproductive system disease 11.0 SERPINA3 MIR9-1 MIR486-1 MIR34C MIR31 MIR30A
46 connective tissue disease 11.0 SERPINA3 MIR9-1 MIR486-1 MIR34C MIR31 MIR30A
47 endocrine gland cancer 11.0 SERPINA3 MIR9-1 MIR486-1 MIR34C MIR31 MIR30A
48 bladder disease 11.0 MIR9-1 MIR486-1 MIR34C MIR31 MIR30A MIR21
49 cell type cancer 11.0 SERPINA3 MIR9-1 MIR486-1 MIR34C MIR31 MIR30A
50 large intestine cancer 11.0 MIR9-1 MIR486-1 MIR34C MIR31 MIR30A MIR21

Comorbidity relations with Respiratory System Disease via Phenotypic Disease Network (PDN):


Acute Cystitis Bronchitis
Heart Disease Hypertension, Essential
Respiratory Failure

Graphical network of the top 20 diseases related to Respiratory System Disease:



Diseases related to Respiratory System Disease

Symptoms & Phenotypes for Respiratory System Disease

UMLS symptoms related to Respiratory System Disease:


dyspnea, edema, respiratory distress, apnea, hemoptysis, cyanosis, stridor, wheezing, rhinorrhea, inspiratory stridor, sore throat, cheyne-stokes respiration, coughing, hoarseness, anoxemia, labored breathing, expiratory wheeze, inspiratory wheeze, choking sensation, pathological conditions, signs and symptoms, signs and symptoms of ill-defined conditions, pleuritic pain, sinus congestion, other symptoms involving respiratory system and chest, bronchorrhea, neonatal cyanosis, gasping for breath, symptoms involving respiratory system and other chest symptoms, nasal congestion (finding), nasal irritation, neck tightness, larynx pain

Drugs & Therapeutics for Respiratory System Disease

Drugs for Respiratory System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 307)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
2
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
3
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
4
Ciclesonide Approved, Investigational Phase 4 126544-47-6, 141845-82-1 444033
5
Nitric Oxide Approved Phase 4 10102-43-9 145068
6
Azithromycin Approved Phase 4 83905-01-5 55185 447043
7
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
8
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
9
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
10
Polyestradiol phosphate Approved Phase 4 28014-46-2
11
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
12
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
13
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
14
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
15
Ofloxacin Approved Phase 4 82419-36-1 4583
16
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
17
Piperacillin Approved Phase 4 66258-76-2 43672
18
Clarithromycin Approved Phase 4 81103-11-9 84029
19
Tazobactam Approved Phase 4 89786-04-9 123630
20
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
21
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
22
Ceftaroline fosamil Approved, Investigational Phase 4 229016-73-3
23
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
24
Acetaminophen Approved Phase 4 103-90-2 1983
25
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
26
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
27
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
28
Omalizumab Approved, Investigational Phase 4 242138-07-4
29
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
30 cefuroxime axetil Phase 4
31 Penicillin G Benzathine Phase 4
32 Penicillin G Procaine Phase 4
33 Antipyretics Phase 4
34 Adrenergic beta-Agonists Phase 4
35 Bronchodilator Agents Phase 4
36 Vaccines Phase 4
37 Tocolytic Agents Phase 4
38 Cholinergic Antagonists Phase 4
39 Adjuvants, Anesthesia Phase 4
40 Muscarinic Antagonists Phase 4
41 Bromides Phase 4
42
Glycopyrrolate Phase 4 596-51-0 3494
43 Albuterol Phase 4
44 Anti-Infective Agents Phase 4
45 Norgestimate, ethinyl estradiol drug combination Phase 4
46 Contraceptive Agents Phase 4
47 Estradiol 17 beta-cypionate Phase 4
48 Topoisomerase Inhibitors Phase 4
49 Contraceptives, Oral, Combined Phase 4
50 Contraceptives, Oral Phase 4

Interventional clinical trials:

(show top 50) (show all 393)
# Name Status NCT ID Phase Drugs
1 Evaluation and Reconditioning of Marginal Lung Donors to Transplantation by ex Vivo Lung Perfusion Unknown status NCT01353105 Phase 4
2 Normal Oxygenation Maintenance in Intensive Care Unit: Randomized Controlled Trial Unknown status NCT01319643 Phase 4 Oxygen
3 CPAP Application at Delivery Room at Very Low Birth Weight Infants Unknown status NCT01024361 Phase 4
4 Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections. Can Measurement of Procalcitonin Reduce the Use of Antibiotics? Unknown status NCT02171338 Phase 4
5 The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases Completed NCT01867281 Phase 4 aspirin
6 Study to Evaluate the Effect of Roflumilast 500 μg on Exacerbation Rate in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Treated With a Fixed-Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS) Completed NCT01443845 Phase 4 Roflumilast;Placebo
7 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of YMC026 in Respiratory Disease Patients With Cough and Sputum as the Main Symptoms Completed NCT03334916 Phase 4 YMC026;Placebo
8 The Efficacy and Safety of Hyeonggaeyeongyo-tang for Chronic Rhinitis According to Pattern Identification in Korean Medicine Completed NCT02477293 Phase 4 Hyeonggaeyeongyo-tang
9 The Effect of Supplemental Oxygen During Physical Exercise Training on Exercise Capacity in COPD Patients. Completed NCT01150383 Phase 4
10 Double-Blind Placebo-Controlled Clinical Effectiveness Trial of the 23-Valent Pneumococcal Vaccine Among Military Trainees At Increased Risk of Respiratory Disease Completed NCT02079701 Phase 4
11 Feedback Reports and E-learning to Support Spirometry Test Performance in Dutch Family Practices Completed NCT00962455 Phase 4
12 Small Particle Inhaled Steroids in Refractory Steroid-responsive Asthma Completed NCT01171365 Phase 4 Ciclesonide;Placebo
13 A Randomized, Double-blind, Parallel Group, 26-week Study Evaluating the Efficacy, Safety and Tolerability of NVA237 Given Once or Twice Daily, in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease Completed NCT02371629 Phase 4 NVA237;Placebo;Salbutamol
14 Pilot Study to Assess the Effect of Prophylactic Antipyretics on Immune Responses and Rates of Fever After 2013-2014 Inactivated Influenza Vaccine (IIV) in Young Children Completed NCT01946594 Phase 4
15 Effect of Acetazolamide on Lung Water Content by Ultrasound in Patients With Respiratory Disease at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial Recruiting NCT03540901 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
16 Shortened Antibiotic Treatment in Community-Acquired Pneumonia: A Nationwide Danish Randomized Controlled Trial Recruiting NCT04089787 Phase 4
17 Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia Recruiting NCT02735707 Phase 4 Hydrocortisone;Ceftriaxone;Moxifloxacin or Levofloxacin;Piperacillin tazobactam;Ceftaroline;Amoxicillin Clavulanate;Macrolide administered for 3 days;Macrolide administered for up to 14 days
18 Non-specific Effects of Rabies Vaccine on the Incidence of Common Infectious Disease Episodes: a Randomized Controlled Trial Enrolling by invitation NCT03656198 Phase 4 Sterile Water Injection
19 Effect of Celecoxib on Postoperative Narcotic Use and Disease Severity in Patients With Aspirin-exacerbated Respiratory Disease and Chronic Rhinosinusitis: a Randomised Controlled Trial Not yet recruiting NCT04147013 Phase 4 Celecoxib;Placebo
20 Non-Invasive Measures of Distal Lung Disease in Asthmatics Before and After Treatment With Omalizumab Terminated NCT00784485 Phase 4 Xolair injections
21 Efficacy of Vitamin D on the Clinical Management of Pediatric Patients With Asthma in the Hospital General Naval de Alta Especialidad Unknown status NCT02571660 Phase 3 GINA treatment fot asthma +vit.D low supplementation dose;GINA treatment fot asthma +vit.D high supplementation dose
22 Effect of the Preoperative Administration of Dexamethasone in the Respiratory Function and Postoperative Symptoms in Women Undergoing Mastectomy for Cancer. Results of a Randomized Clinical Trial. Unknown status NCT02305173 Phase 3 Intravenous Dexamethasone;intravenous salin water
23 A Multicenter, Non-Randomized, Open Label Trial Of Azithromycin SR For The Treatment Of Acute Bronchitis And Secondary Infection Of Chronic Respiratory Diseases In Japan Adults Completed NCT00360464 Phase 3 Azithromycin SR
24 The Effect of Probiotics on Infections in Toddlers Completed NCT00823056 Phase 3
25 Validation of a Simulated Clinical Evaluation of Ventilators Completed NCT01113255 Phase 2, Phase 3
26 Real Life Effectiveness in Asthma of Symbicort Single Inhaler Therapy Completed NCT00319306 Phase 3 Budesonide/formoterol
27 A Multi-Center, Multinational, Randomized, Double-Blind, Parallel Group Study of the Effects of Ciclesonide Hfa-Mdi 640 μg/Day and Beclomethasone Hfa-Mdi 640 μg/Day on Lens Opacification in Adult Subjects With Moderate to Severe Persistent Asthma Completed NCT00254956 Phase 3 ciclesonide (XRP1526)
28 A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients With Uncontrolled Asthma Completed NCT01928771 Phase 3
29 A Multicentre, Randomized, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Asthmatic Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist (CALIMA) Completed NCT01914757 Phase 3
30 A Multicenter, Open-Label, Functionality, Reliability and Performance Study of a Single-Use Auto-Injector With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GRECO) Completed NCT02918071 Phase 3
31 A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma. Completed NCT02322775 Phase 3
32 A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE) Completed NCT02417961 Phase 3
33 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001 Completed NCT00382408 Phase 3
34 CSP #574 - Evaluate the Safety and Efficacy of Methylprednisolone in Hospitalized Veterans With Severe Community-Acquired Pneumonia Completed NCT01283009 Phase 3 Methylprednisolone
35 A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation Completed NCT02869438 Phase 3 Benralizumab
36 A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-563) to Reduce Oral Corticosteroid Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus Long-acting β2 Agonist and Chronic Oral Corticosteroid Therapy (ZONDA) Completed NCT02075255 Phase 3
37 A Phase III, Multi-Center, Randomized, Parallel-Group, Placebo-Controlled and Double- Blind Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Perennial Allergic Rhinitis Completed NCT01918033 Phase 3 Desloratadine 5 mg;Placebo
38 A Randomized, Placebo-Controlled Trial to Evaluate the Effects of Phenylephrine HCl 30 mg Extended-Release Tablets on Nasal Congestion in Subjects With Allergic Rhinitis Completed NCT01413958 Phase 3 Phenylephrine;Placebo;Loratadine
39 A Randomised, Double-blind, Double Dummy, 56 Week Placebo-controlled, Multicentre, Parallel Group, Phase 3 Study Evaluating Efficacy/Safety of 3 Benralizumab Doses in Patients With Moderate to Very Severe COPD With Previous Exacerbations. Completed NCT02155660 Phase 3 Benralizumab Arm A;Benralizumab Arm B;Benralizumab Arm C;Placebo
40 Randomised, Double-blind, 56 Week Placebo-controlled, Parallel Group, Multicentre, Phase 3 Study to Evaluate the Efficacy and Safety of 2 Doses of Benralizumab in Patients With Moderate to Very Severe COPD With a History of Exacerbations Completed NCT02138916 Phase 3 Benralizumab Arm A;Benralizumab Arm B;Placebo
41 A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients Completed NCT01709864 Phase 3 NVA237;Placebo
42 A Multicentre, Double-blind, Randomized, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus Long-acting β2 Agonist (BORA) Completed NCT02258542 Phase 3
43 A Randomized, Controlled Phase III Trial to Evaluate the Efficacy of Elortinib vs Gefitinib in Advanced Non-small-cell Lung Cancer With EGFR Exon 19 or 21 Mutations Completed NCT01024413 Phase 3 erlotinib;gefitinib
44 Cluster-randomised, Double-Blind, Placebo-Controlled Trial of Vitamin D Supplementation for the Prevention of Influenza and Other Respiratory Infections in Sheltered Accommodation (ViDiFlu) Completed NCT01069874 Phase 2, Phase 3
45 A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients Completed NCT01715298 Phase 3 NVA237;Placebo
46 A Phase III Study to Assess Immunogenicity and Safety of 4th LBVH0101 Vaccination Compared With 4th Hiberix™ Vaccination in Healthy Toddlers Who Completed Primary Vaccination in LG-VHCL002 Study Completed NCT01251133 Phase 3
47 A Randomized, Observer-blind, Multicenter, Phase 3 Study to Evaluate the Lot Consistency, Immunogenicity, and Safety of a Plant-Derived Quadrivalent Virus-Like Particle Influenza Vaccine in Healthy Adults 18-49 Years of Age Completed NCT03321968 Phase 3
48 Intranasal Ketamine for Peripheral Venous Puncture in Pediatric Patients: A Randomized Double Blind and Placebo Controlled Study Completed NCT02929524 Phase 2, Phase 3 Ketamine;Placebo
49 A Randomized, Observer-blind, Active Comparator-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-derived Quadrivalent VLP Influenza Vaccine in Adults 65 Years of Age and Older Completed NCT03739112 Phase 3
50 A Randomized, Observer-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Adults 18-64 Years of Age Completed NCT03301051 Phase 3

Search NIH Clinical Center for Respiratory System Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Glycopyrrolate
nalmefene
Nalmefene hydrochloride
Naloxone Hydrochloride
prednisolone
prednisolone acetate
PREDNISOLONE ACETATE PWDR
PREDNISOLONE PWDR
Prednisolone sodium phosphate
prednisolone tebutate
Prednisone
PREDNISONE PWDR

Genetic Tests for Respiratory System Disease

Genetic tests related to Respiratory System Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Respiratory System 29

Anatomical Context for Respiratory System Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Respiratory System Disease:

19
Respiratory System Which Extends From The Nasal Sinuses To The Diaphragm

MalaCards organs/tissues related to Respiratory System Disease:

40
Lung, Testes, Thyroid, Heart, Bone, Breast, Skin

Publications for Respiratory System Disease

Articles related to Respiratory System Disease:

(show top 50) (show all 58)
# Title Authors PMID Year
1
Early famine exposure and adult disease risk based on a 10-year prospective study of Chinese adults. 61
31704783 2020
2
[Using of pre-hospital emergency resources by acute alcoholism patients in a hospital in Guangzhou: a data survey from 2009 to 2018]. 61
31898575 2019
3
The impact of ambient particulate matter on hospital outpatient visits for respiratory and circulatory system disease in an urban Chinese population. 61
30812001 2019
4
Toxoplasma gondii in four captive kangaroos (Macropus spp.) in China: Isolation of a strain of a new genotype from an eastern grey kangaroo (Macropus giganteus). 61
30923671 2019
5
Early warning signals for critical transitions in cardiopulmonary health, related to air pollution in an urban Chinese population. 61
30219611 2018
6
Valsartan attenuates bleomycin-induced pulmonary fibrosis by inhibition of NF-κB expression and regulation of Th1/Th2 cytokines. 61
29447007 2018
7
Neighbouring green space and mortality in community-dwelling elderly Hong Kong Chinese: a cohort study. 61
28765127 2017
8
Characteristics of Traditional Chinese Medicine Use in Pediatric Cancer Patients: A Nationwide, Retrospective, Taiwanese-Registry, Population-Based Study. 61
27405933 2017
9
[Computer-aided Diagnosis and New Electronic Stethoscope]. 61
29862758 2017
10
IMPACT OF SULPHUR DIOXIDE ON THE RESPIRATORY SYSTEM OF TBILISI POPULATION. 61
28574394 2017
11
Hospital admissions for respiratory system diseases in adults with intellectual disabilities in Southeast London: a register-based cohort study. 61
28360254 2017
12
[Recent progress of IncRNA in respiratory system disease]. 61
27852369 2016
13
[Status of two-week illness for primary and secondary students in middle and west provinces]. 61
27807333 2016
14
[Application of electronic bronchoscopy in pediatric intensive care patients with difficult ventilator weaning]. 61
27530791 2016
15
Respiratory System Disease. 61
27469180 2016
16
[Analysis on causes of death of residents in Beijing, 1965-1974]. 61
27453108 2016
17
Risk Factors for Acute Kidney Injury after Cardiovascular Surgery: Evidence from 2,157 Cases and 49,777 Controls - A Meta-Analysis. 61
27275160 2016
18
The impact of PM2.5 on the human respiratory system. 61
26904255 2016
19
[Study on burden of disease in Chongqing, 2010-2013]. 61
26837360 2015
20
Tic disorders in the differential diagnosis of chronic cough in children in relation to four cases. 61
26568694 2015
21
Fine Particulate Matter Pollution and Hospital Admissions for Respiratory Diseases in Beijing, China. 61
26402691 2015
22
Preoperative FeNO as a screening indicator of pulmonary complications after abdominal surgery in patients over 60 years old. 61
25992977 2015
23
Asthma-chronic obstructive pulmonary disease overlap syndrome in Poland. Findings of an epidemiological study. 61
25610352 2014
24
[Research progress about the relationship between nanoparticles silicon dioxide and lung cancer]. 61
25342044 2014
25
Efficient post-disaster patient transportation and transfer: experiences and lessons learned in emergency medical rescue in Aceh after the 2004 Asian tsunami. 61
25102536 2014
26
Survival in systemic lupus erythematosus, 1995-2010. A prospective study in a Danish community. 61
23873432 2013
27
[Spatial distribution of inhalable particulate and association with respiratory disease in Beijing City]. 61
23487945 2013
28
[What temperature index is the best predictor for the impact of temperature on mortality]. 61
23363873 2012
29
Comparison of risk factors for recurrent respiratory infections between urban and rural preschool children in Yiwu, China. 61
22573425 2012
30
Clinical pharmacists on medical care of pediatric inpatients: a single-center randomized controlled trial. 61
22292061 2012
31
[Optimisation of diagnostics and differential diagnostics disseminated pulmonary tuberculosis]. 61
23457976 2012
32
Medical and social problems among women headed families in Baghdad. 61
25003041 2012
33
The evolution of academic performance in nine subspecialties of internal medicine: an analysis of journal citation reports from 1998 to 2010. 61
23118973 2012
34
Impact of morbidity and life events on successful aging. 61
21727083 2011
35
[Epidemiological study of women adults with mixed urinary incontinence in China]. 61
20973221 2010
36
Mortality patterns of Army Chemical Corps veterans who were occupationally exposed to herbicides in Vietnam. 61
20382334 2010
37
Epidemiology of mixed urinary incontinence in China. 61
20022321 2010
38
Indoor air pollution as a lung health hazard: focus on populous countries. 61
19532032 2009
39
[Tobacco smoking among young patients with bronchial asthma and determination of smoking-related behavior in the patient's closest environment]. 61
19603694 2009
40
Canada's global position in life expectancy: a longitudinal comparison with the healthiest countries in the world. 61
19263968 2009
41
Hypercapnia and hypocapnia in neonates. 61
18822927 2008
42
Identification of regional air pollution characteristic and the correlation with public health in Taiwan. 61
17617673 2007
43
Helicobacter pylori infection as a possible risk factor for respiratory system disease: a review of the literature. 61
16759841 2007
44
Predictors of mortality in acute renal failure in a developing country: a prospective study. 61
17497470 2007
45
Complications following D3 gastrectomy: post hoc analysis of a randomized trial. 61
16369704 2006
46
Nutritional status of patients hospitalized in pediatric clinic. 61
16547850 2005
47
[Vascular risk factors in primary open angle glaucoma]. 61
15644886 2004
48
[Pulmonary function and nutrition]. 61
15143398 2003
49
[New clinical tests that physicians should know for diagnosis of respiratory system disease]. 61
9867006 1998
50
Morbidity and mortality after radical gastrectomy for patients with carcinoma of the stomach. 61
7599767 1995

Variations for Respiratory System Disease

ClinVar genetic disease variations for Respiratory System Disease:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 46;XY;t(9;14)(p21;q12)dnTranslocation Uncertain significance 267914

Expression for Respiratory System Disease

Search GEO for disease gene expression data for Respiratory System Disease.

Pathways for Respiratory System Disease

Pathways related to Respiratory System Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.89 MIR9-1 MIR34C MIR31 MIR30A MIR21 MIR200B
2 11.06 MIR34C MIR30A MIR17
3 10.27 MIR199A1 MIR145

GO Terms for Respiratory System Disease

Cellular components related to Respiratory System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.4 SERPINA3 MIR486-1 MIR31 MIR30A MIR21 MIR199A1

Biological processes related to Respiratory System Disease according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.97 MIR30A MIR21 MIR155 MIR140 MIR125A
2 negative regulation of gene expression GO:0010629 9.85 MIR21 MIR200B MIR17 MIR155 MIR125A
3 cellular response to hypoxia GO:0071456 9.8 MIR17 MIR155 MIR140 MIR126
4 negative regulation of angiogenesis GO:0016525 9.78 MIR21 MIR200B MIR145 MIR125A
5 positive regulation of inflammatory response GO:0050729 9.77 MIR21 MIR155 MIR126
6 positive regulation of angiogenesis GO:0045766 9.72 MIR31 MIR30A MIR21 MIR199A1 MIR126
7 positive regulation of blood vessel endothelial cell migration GO:0043536 9.7 MIR31 MIR30A MIR126
8 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.69 MIR21 MIR199A1 MIR145
9 negative regulation of JAK-STAT cascade GO:0046426 9.61 MIR9-1 MIR155
10 negative regulation of innate immune response GO:0045824 9.61 MIR21 MIR155
11 positive regulation of activated T cell proliferation GO:0042104 9.61 MIR21 MIR155 ICOSLG
12 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.6 MIR17 MIR155
13 positive regulation of microglial cell activation GO:1903980 9.58 MIR155 MIR142
14 positive regulation of metalloendopeptidase activity GO:1904685 9.58 MIR21 MIR17
15 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.58 MIR199A1 MIR17 MIR155
16 negative regulation of regulatory T cell differentiation GO:0045590 9.56 MIR21 MIR155
17 positive regulation of sprouting angiogenesis GO:1903672 9.56 MIR31 MIR155 MIR126 MIR125A
18 miRNA mediated inhibition of translation GO:0035278 9.56 MIR9-1 MIR31 MIR30A MIR21 MIR200B MIR17
19 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.55 MIR21 MIR17
20 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.54 MIR31 MIR155
21 positive regulation of connective tissue replacement GO:1905205 9.54 MIR34C MIR199A1 MIR155
22 gene silencing by miRNA GO:0035195 9.47 MIR9-1 MIR34C MIR31 MIR30A MIR21 MIR200B
23 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.46 MIR34C MIR199A1 MIR17 MIR155

Molecular functions related to Respiratory System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.44 MIR9-1 MIR31 MIR30A MIR21 MIR200B MIR199A1
2 RNA polymerase II complex binding GO:0000993 9.26 MIR145 MIR140 MIR126 MIR125A

Sources for Respiratory System Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....